Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

This study is exploring whether patients prefer getting their immunotherapy (checkpoint inhibitor drugs like nivolumab or pembrolizumab) as a shot under the skin rather than through an IV infusion. It is looking at patient satisfaction, convenience, and quality of life across several cancer types. **You may be eligible if...** - You are an adult with a locally advanced or metastatic solid tumor cancer for which nivolumab or pembrolizumab is an approved treatment - You are either new to immunotherapy (treatment-naive) or already receiving a PD-1/PD-L1-based immunotherapy - You are willing and able to read English and sign informed consent - Eligible cancer types include kidney cancer, melanoma, lung cancer, bladder cancer, head and neck cancers, liver cancer, colorectal cancer with certain features, esophageal/gastric cancer, cervical cancer, and others **You may NOT be eligible if...** - You are not eligible to receive nivolumab or pembrolizumab for your cancer type per your oncologist - You are unable to read English Talk to your doctor to see if this trial is right for you.